United States' experience in nuchal translucency measurement: variation according to provider characteristics in over five million ultrasound examinations.


Journal

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
ISSN: 1469-0705
Titre abrégé: Ultrasound Obstet Gynecol
Pays: England
ID NLM: 9108340

Informations de publication

Date de publication:
Nov 2021
Historique:
revised: 07 02 2021
received: 24 12 2020
accepted: 12 02 2021
pubmed: 27 2 2021
medline: 28 12 2021
entrez: 26 2 2021
Statut: ppublish

Résumé

The Nuchal Translucency Quality Review (NTQR) program has provided standardized education, credentialing and epidemiological monitoring of nuchal translucency (NT) measurements since 2005. Our aim was to review the effect on NT measurement of provider characteristics since the program's inception. We evaluated the distribution of NT measurements performed between January 2005 and December 2019, for each of the three primary performance indicators of NT measurement (NT median multiples of the median (MoM), SD of log Of 5 216 663 NT measurements from 9340 providers at 3319 sites, the majority (75%) of providers had an NT median MoM within the acceptable range of 0.9-1.1 and 85.5% had NT median MoM not statistically significantly outside this range. Provider characteristics associated with measurement within the expected range of performance included higher volume of NT scans performed annually, practice at a site with larger numbers of other NT-credentialed providers, longer duration of participation in the NTQR program and alternative initial credentialing pathway. Annual scan volume, duration of participation in the NTQR program, alternative initial credentialing pathway and number of other NT-credentialed providers within the practice are all associated with outcome metrics indicating quality of performance. It is critical that providers participate in ongoing quality assessment of NT measurement to maintain consistency and precision. Ongoing assessment programs with continuous feedback and education are necessary to maintain quality care. © 2021 International Society of Ultrasound in Obstetrics and Gynecology.

Identifiants

pubmed: 33634915
doi: 10.1002/uog.23621
doi:

Types de publication

Evaluation Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

732-737

Informations de copyright

© 2021 International Society of Ultrasound in Obstetrics and Gynecology.

Références

Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Fetal Medicine Foundation First Trimester Screening Group. Lancet 1998; 352: 343-346.
Evans MI, Van Decruyes H, Nicolaides KH. Nuchal translucency measurements for first-trimester screening: the ‘price’ of inaccuracy. Fetal Diagn Ther 2007; 22: 401-404.
Brizot ML, Carvalho MH, Liao AW, Reis NS, Armbruster-Moraes E, Zugaib M. First-trimester screening for chromosomal abnormalities by fetal nuchal translucency in a Brazilian population. Ultrasound Obstet Gynecol 2001; 18: 652-655.
Gasiorek-Wiens A, Tercanli S, Kozlowski P, Kossakiewicz A, Minderer S, Meyberg H, Kamin G, Germer U, Bielicki M, Hackeloer BJ, Sarlay D, Kuhn P, Klapp J, Bahlmann F, Pruggmayer M, Schneider KT, Seefried W, Fritzer E, von Kaisenberg CS; German-Speaking Down Syndrome Screening Group. Screening for trisomy 21 by fetal nuchal translucency and maternal age: a multicenter project in Germany, Austria and Switzerland. Ultrasound Obstet Gynecol 2001; 18: 645-648.
Theodoropoulos P, Lolis D, Papageorgiou C, Papaioannou S, Plachouras N, Makrydimas G. Evaluation of first-trimester screening by fetal nuchal translucency and maternal age. Prenat Diagn 1998; 18: 133-137.
Zoppi MA, Ibba RM, Floris M, Monni G. Fetal nuchal translucency screening in 12 495 pregnancies in Sardinia. Ultrasound Obstet Gynecol 2001; 18: 649-651.
D'Alton ME, Fuchs KM, Abuhammad A, Benacerraf B, Berkowitz R, Cuckle H, Depp R, Goldberg J, O'Keeffe D, Platt LD, Spitz JL, Toland G, Wapner R; Nuchal Translucency Quality Review Program. Implementation of a national nuchal translucency education and quality monitoring program. Obstet Gynecol 2014; 123: 149-154.
Schmidt P, Staboulidou I, Elsasser M, Vaske B, Hillemanns P, Scharf A. How imprecise may the measurement of fetal nuchal translucency be without worsening first-trimester screening? Fetal Diagn Ther 2008; 24: 291-295.
Snijders RJ, Thom EA, Zachary JM, Platt LD, Greene N, Jackson LG, Sabbagha RE, Filkins K, Silver RK, Hogge WA, Ginsberg NA, Beverly S, Morgan P, Blum K, Chilis P, Hill LM, Hecker J, Wapner RJ. First-trimester trisomy screening: nuchal translucency measurement training and quality assurance to correct and unify technique. Ultrasound Obstet Gynecol 2002; 19: 353-359.
Cuckle H, Platt LD, Thornburg LL, Bromley B, Fuchs K, Abuhamad A, Benacerraf B, Copel JA, Depp R, D'Alton M, Goldberg J, O'Keeffe D, Spitz J, Toland G, Wapner R; Nuchal Translucency Quality Review Program of the Perinatal Quality Foundation. Nuchal Translucency Quality Review (NTQR) program: first one and half million results. Ultrasound Obstet Gynecol 2015; 45: 199-204.
Sahota DS, Chen M, Leung TY, Chan LW, Fung TY, Ting YH, Lau TK. Assessment of sonographer nuchal translucency measurement performance-central tendency and dispersion. J Matern Fetal Neonatal Med 2011; 24: 812-816.
Wapner RJ. First trimester screening: the BUN study. Semin Perinatol 2005; 29: 236-239.
Wapner R, Thom E, Simpson JL, Pergament E, Silver R, Filkins K, Platt L, Mahoney M, Johnson A, Hogge WA, Wilson RD, Mohide P, Hershey D, Krantz D, Zachary J, Snijders R, Greene N, Sabbagha R, MacGregor S, Hill L, Gagnon A, Hallahan T, Jackson L; First Trimester Maternal Serum Biochemistry and Fetal Nuchal Translucency Screening (BUN) Study Group. First-trimester screening for trisomies 21 and 18. N Engl J Med 2003; 349: 1405-1413.
Zohav E, Dunsky A, Segal O, Peled R, Herman A, Segal S. The effects of maternal and fetal parameters on the quality of nuchal translucency measurement. Ultrasound Obstet Gynecol 2001; 18: 638-640.
Malone FD, D'Alton ME; Society for Maternal-Fetal Medicine. First-trimester sonographic screening for Down syndrome. Obstet Gynecol 2003; 102: 1066-1079.
Malone FD. Nuchal translucency-based Down syndrome screening: barriers to implementation. Semin Perinatol 2005; 29: 272-276.
Malone FD, Canick JA, Ball RH, Nyberg DA, Comstock CH, Bukowski R, Berkowitz RL, Gross SJ, Dugoff L, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, Dukes K, Bianchi DW, Rudnicka AR, Hackshaw AK, Lambert-Messerlian G, Wald NJ, D'Alton ME; First- and Second-Trimester Evaluation of Risk (FASTER) Research Consortium. First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med 2005; 353: 2001-2011.
Logghe H, Cuckle H, Sehmi I. Centre-specific ultrasound nuchal translucency medians needed for Down syndrome screening. Prenat Diagn 2003; 23: 389-392.
Nisbet D, Robertson A, Mannil B, Pincham V, McLennan A. Quality management of nuchal translucency ultrasound measurement in Australia. Aust N Z J Obstet Gynaecol 2019; 59: 54-58.
Cuckle H. Monitoring quality control of nuchal translucency. Clin Lab Med 2010; 30: 593-604.
Maya I, Yacobson S, Kahana S, Yeshaya J, Tenne T, Agmon-Fishman I, Cohen-Vig L, Shohat M, Basel-Vanagaite L, Sharony R. Cut-off value of nuchal translucency as indication for chromosomal microarray analysis. Ultrasound Obstet Gynecol 2017; 50: 332-335.
Tomai XH, Schaaps JP, Foidart JM. Fetal nuchal translucency thickness in different cut-off points for aneuploidy screening in the south of Vietnam. J Obstet Gynaecol Res 2011; 37: 1327-1334.
Comstock CH, Malone FD, Ball RH, Nyberg DA, Saade GR, Berkowitz RL, Ferreira J, Dugoff L, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, Bianchi DW, D'Alton ME; FASTER Research Consortium. Is there a nuchal translucency millimeter measurement above which there is no added benefit from first trimester serum screening? Am J Obstet Gynecol 2006; 195: 843-847.
Evans MI, Krantz DA, Hallahan T, Sherwin J, Britt DW. Quality of nuchal translucency measurements correlates with broader aspects of program rigor and culture of excellence. Fetal Diagn Ther 2013; 33: 230-234.
Abele H, Hoopmann M, Wright D, Hoffmann-Poell B, Huettelmaier M, Pintoffl K, Wallwiener D, Kagan KO. Intra- and interoperator reliability of manual and semi-automated measurement of fetal nuchal translucency by sonographers with different levels of experience. Ultrasound Obstet Gynecol 2010; 36: 417-422.
Koster MP, Wortelboer EJ, Engels MA, Stoutenbeek PH, Elvers LH, Visser GH, Schielen PC. Quality of nuchal translucency measurements in The Netherlands: a quantitative analysis. Ultrasound Obstet Gynecol 2009; 34: 136-141.
Palomaki GE, Neveux LM, Donnenfeld A, Lee JE, McDowell G, Canick JA, Summers A, Lambert-Messerlian G, Kellner LH, Zebelman A, Haddow JE. Quality assessment of routine nuchal translucency measurements: a North American laboratory perspective. Genet Med 2008; 10: 131-138.
Zoppi MA, Ibba RM, Putzolu M, Floris M, Monni G. Assessment of risk for chromosomal abnormalities at 10-14 weeks of gestation by nuchal translucency and maternal age in 5,210 fetuses at a single centre. Fetal Diagn Ther 2000; 15: 170-173.
D'Alton ME, Cleary-Goldman J, Lambert-Messerlian G, Ball RH, Nyberg DA, Comstock CH, Bukowski R, Berkowitz RL, Dar P, Dugoff L, Craigo SD, Timor IE, Carr SR, Wolfe HM, Dukes K, Canick JA, Malone FD. Maintaining quality assurance for sonographic nuchal translucency measurement: lessons from the FASTER Trial. Ultrasound Obstet Gynecol 2009; 33: 142-146.
Herman A, Dreazen E, Maymon R, Tovbin Y, Bukovsky I, Weinraub Z. Implementation of nuchal translucency image-scoring method during ongoing audit. Ultrasound Obstet Gynecol 1999; 14: 388-392.
Fries N, Althuser M, Fontanges M, Talmant C, Jouk PS, Tindel M, Duyme M. Quality control of an image-scoring method for nuchal translucency ultrasonography. Am J Obstet Gynecol 2007; 196: 272.e1-5.
Pajkrt E, Mol BW, Boer K, Drogtrop AP, Bossuyt PM, Bilardo CM. Intra- and interoperator repeatability of the nuchal translucency measurement. Ultrasound Obstet Gynecol 2000; 15: 297-301.

Auteurs

L L Thornburg (LL)

Department of Obstetrics and Gynecology, University of Rochester Medical Center, Rochester, NY, USA.

B Bromley (B)

Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA, USA.

L Dugoff (L)

Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA, USA.

L D Platt (LD)

David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California, Los Angeles, CA, USA.
Center for Fetal Medicine and Women's Ultrasound, Los Angeles, CA, USA.

K M Fuchs (KM)

Department of Obstetrics and Gynecology, Columbia University Medical Center, New York, NY, USA.

M E Norton (ME)

Department of Obstetrics and Gynecology and Reproductive Sciences, University of California San Francisco, San Francisco, CA, USA.

J McIntosh (J)

Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI, USA.

G J Toland (GJ)

Perinatal Quality Foundation, Oklahoma City, OK, USA.

H Cuckle (H)

Tel Aviv University, Faculty of Medicine, Ramat Aviv, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH